Investigational drug · Phase 3
SI-B001
Not approved by FDA. In 9 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
9
9 still active
All registered trials
11
Any phase or sponsor naming "SI-B001"
First trial start
2021
Oct 20, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SI-B001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Head and Neck Squamous Cell Carcinoma
- Non-small Cell Lung Cancer
- Squamous Cell Carcinoma of Head and Neck
- Non-small Cell Lung Adenocarcinoma
- Squamous Cell Carcinoma of Lung
- Esophageal Squamous Cell Carcinomas
- Non Small Cell Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Stomach and esophageal cancer · Head and neck cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "SI-B001" as an intervention, largest first.
- A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell CarcinomaPivotal-lookingActive, not recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT05943795 · 589 participants · Start Jul 14, 2023 · Primary completion Jul 2026
Drug: SI-B001; Docetaxel · For: Non-small Cell Lung Adenocarcinoma; Squamous Cell Carcinoma of Lung
Sites: Guangzhou, China; Hangzhou, China
- A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung CancerActive, not recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT05949606 · 95 participants · Start Oct 30, 2023 · Primary completion Dec 2026
Drug: SI-B001; SI-B003 · For: Non-small Cell Lung Cancer
Sites: Shanghai, China
- A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT05668858 · 70 participants · Start Feb 10, 2023 · Primary completion Dec 2026
Drug: SI-B001; SI-B003 · For: Squamous Cell Carcinoma of Head and Neck
Sites: Shanghai, China
- SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.Active, not recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT05020457 · 69 participants · Start Dec 7, 2021 · Primary completion Dec 2025
Drug: SI-B001; AP or TP and 1 more · For: Non Small Cell Lung Cancer
Sites: Chongqing, China; Guangzhou, China; Guilin, China · 6 sites in all
- A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial TumorsActive, not recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT04603287 · 60 participants · Start Apr 17, 2020 · Primary completion Dec 2025
Drug: SI-B001 · For: Locally Advanced or Metastatic Epithelial Tumor
Sites: Guangzhou, China; Chengdu, China; Hangzhou, China
- A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT06668961 · 48 participants · Start Nov 7, 2024 · Primary completion Nov 2026
Drug: SI-B001; SI-B003 · For: Head and Neck Squamous Cell Carcinoma
Sites: Shanghai, China
- A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCCActive, not recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT05054439 · 45 participants · Start Dec 22, 2021 · Primary completion Dec 2026
Drug: SI-B001; Paclitaxel and 1 more · For: Head and Neck Squamous Cell Carcinoma
Sites: Guilin, China; Guiyang, China; Wuhan, China · 7 sites in all
- SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.Active, not recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT05022654 · 22 participants · Start Dec 13, 2021 · Primary completion Dec 2025
Drug: SI-B001; Irinotecan · For: Esophageal Squamous Cell Carcinomas
Sites: Beijing, China; Anyang, China; Luoyang, China · 6 sites in all
- SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.Pivotal-lookingActive, not recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT05020769 · 14 participants · Start Jan 6, 2022 · Primary completion Dec 2025
Drug: SI-B001; Osimertinib · For: Non-small Cell Lung Cancer
Sites: Guangzhou, China; Guilin, China; Guangdong, China
- A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCCActive, not recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT05044897 · 11 participants · Start Oct 20, 2021 · Primary completion Dec 2025
Drug: SI-B001 · For: Head and Neck Squamous Cell Carcinoma
Sites: Guilin, China; Guiyang, China; Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study.
Xue J, Ma Y, Zhao Y, et al. · Clin Cancer Res 2025
- Prediction of Human Pharmacokinetics and Clinical Effective Dose of SI-B001, an EGFR/HER3 Bi-specific Monoclonal Antibody.
Xue J, Kong D, Yao Y, et al. · J Pharm Sci 2020
Also in development for Head and Neck Squamous Cell Carcinoma
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- Telisotuzumab AdizutecanABBV-400Phase 316 trials
AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- AK117Phase 314 trials
Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- ZanzalintinibXL092Phase 311 trials
Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.